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The clinical evidence base for low-dose computed tomography (LDCT) lung cancer screening is 
rapidly advancing and the case for implementing a UK programme building.  This is welcome news to 
the lung cancer community whose patients too often face a bleak prognosis, in part because early 
diagnosis is so infrequent.  Relatively less attention however, has been paid to the potential 
psychological responses of high-risk individuals to such a screening programme; something which 
should inform policy decision-makers and shape health care professionals’ practice of screening, to 
maximise patient benefit and well-being.   
Previous research on screening for other types of cancer has shown there is potential for patients to 
experience distress at any point along the screening pathway.  An individual’s propensity to 
experience distress in response to cancer screening may be determined in part by the nature of the 
result they receive and any ensuing tests or surveillance, as well as their psychosocial 
characteristics[1].  In this issue of Thorax, Kate Brain and colleagues provide an invaluable 
contribution to both these aspects and the first from the UK; reporting the long-term psychosocial 
outcomes of screening among participants in the UK Lung Screening (UKLS) trial[2].   
The psychological cost of abnormal findings is especially important to understand in the context of 
LDCT lung cancer screening because they are frequent, with an average pulmonary nodule detection 
rate of 20% across trials[3].  In the US National Lung Screening Trial (NLST), 39% of participants 
received a positive screening result for one of their three annual screens, of which 96% were false 
positives[4].  Incidental findings (i.e. medical conditions other than lung cancer) were also a common 
outcome for screenees, affecting 10% of NLST participants following their prevalence (first) 
screen[4].  The UKLS investigators made a distinction between false positive and indeterminate 
results based on their clinical management.  Pulmonary nodules which were immediately suspicious 
for cancer and referred to a multidisciplinary team (MDT) were categorised as ‘false positive’ if 
found to be benign, whereas nodules under surveillance using interval scans were termed 
‘indeterminate’.  The rates were 3.6% and 23% respectively, similar to the Dutch-Belgian trial 
NELSON[5]. 
A diagnosis of lung cancer carries significant distress, but any abnormality associated with lung 
cancer could induce anxiety, and uncertain or prolonged periods of surveillance may be difficult to 
tolerate.  Brain and colleagues found that distress was significantly increased among UKLS 
participants receiving abnormal screening results and requiring repeat imaging.  However, these 
effects were diminished at the two years’ follow-up and did not breach clinically significant 
thresholds.  Anxiety was highest among those under investigation for major lung abnormalities, but 
again this anxiety appeared to be resolved at follow-up.  Previous trials have also observed 
significant short-term screening-induced distress[6–9], and similarly, systematic reviews of this area 
have found no evidence that this distress persists beyond six months[10,11].  Among NLST 
participants, those diagnosed with lung cancer reported impairments in health-related quality of life 
but this was not true for other abnormal results at either one or six months’ follow-up, relative to 
those receiving negative results[12].   
The UKLS findings are therefore promising, as are those from other screening trials.  However, as the 
authors acknowledge, longer term adverse psychological outcomes should continue to be 
researched because there are important differences between the trial and health service contexts.  
The most obvious is that the UKLS trial participants were a self-selected group, and there is evidence 
  
from the Danish Lung Cancer Screening Trial (DLCST) to suggest they could be less vulnerable to 
distress[13].  Indeed, disparities in participation have been a particular problem for lung cancer 
screening.  Fewer current smokers and individuals of a lower socioeconomic position (SEP) have 
participated across European and US trials (e.g. 13,14]; a paradox whereby those at higher risk and 
most likely to benefit appear to be less likely to consider screening.  Importantly, Brain and 
colleagues also identified current smoking status as a potential risk factor for heightened screening 
distress.  While socioeconomic deprivation was not independently associated with distress, the 
Liverpool recruitment site was, where levels of deprivation were highest.  Distress was also higher 
among women (again, fewer of whom took part in UKLS), those who were younger and individuals 
who had experience of lung cancer.  Poorer health-related quality of life and increased anxiety have 
previously been observed among current smokers, those with a longer smoking history, and 
individuals with a lower level of education in the NELSON[6,7] and PLuSS[8] screening cohorts.   
Therefore, the UKLS results suggest that some of the same factors associated with non-participation 
and increased risk of lung cancer may constitute risk factors for worse psychosocial outcomes.  From 
a psychological perspective, this touches on an important deviation of lung cancer screening from 
existing UK cancer screening programmes: the invitation of those at high risk and predominantly due 
to a behavioural risk factor.  Baseline levels of lung cancer worry and distress could therefore already 
be high, to which screening has the potential to contribute but also relieve and reassure.  For some, 
screening may prompt conscious awareness of risk and a prospect of diagnosis that is difficult to 
cope with, potentially exacerbated by the perceived stigmatisation of smoking-related risk. Higher 
affective perceptions of risk[15] and guilt about smoking[16] have been shown to predict higher 
screening-related distress.  Indeed, there is some evidence (albeit mixed) to suggest that enrolment 
into a lung cancer screening trial causes distress, with the DLCST trial finding higher levels of distress 
among the no-screen controls[17].  This is contrary to the results of the UKLS study, and probably 
explained by the fact that the DLCST control group were also required to regularly attend clinics.  
This would not be an issue in the event of a national screening programme because all those who 
are at high risk and eligible would subsequently be offered the screening test.  Nevertheless, it is 
interesting because it implies that screening may offer a means of managing anxiety about higher 
perceived risk.  Smokers have been shown to have more fatalistic views towards cancer[18] and 
perhaps screening could provide a means of instilling a greater sense of control over respiratory 
health and risk of lung cancer mortality, that long-term addiction to tobacco may have quashed.  
Indeed, concern has been raised about the interpretation of a negative screen as a ‘licence to 
smoke’, but alternatively positive responses could be researched and capitalised on to promote 
smoking cessation.  Studies are needed which examine lung cancer-related distress against a 
comparable high-risk sample who are blind to the prospect of screening. 
If the opportunity arises in the UK, the full spectrum of psychological responses to a regular long-
term screening programme need also to be measured.  The accumulation of abnormal findings, or 
the reassurance offered by long-term enrolment in a regular programme, could lead to different 
outcomes.  Potential implications of abnormal results for screening engagement should also be 
examined as the UKLS study found lower decisional satisfaction (about taking part in the trial) among 
participants recalled for a repeat scan, and in the Prostate, Lung, Colorectal and Ovarian (PLCO) 
cancer screening trial, false positive results predicted poorer trial adherence[19].  The development 
and use of condition-specific measures, such as that by Brodersen and colleagues[20], may aid such 
a research agenda.  Specific measures are likely to be more sensitive, and have the potential to 
  
advance understanding of the root causes of distress among specific sub-groups from which 
targeted interventions could be developed.  More generally, and to share the conclusions of Brain 
and colleagues, supportive interventions and communication strategies, especially for those 
identified as at greater risk of distress, should be developed in adjunct to the implementation of 
screening in the event of a national programme.  Previous studies of pulmonary nodules detected 
incidentally find that the quality of communication is positively associated with psychological well-
being[21].  The same care and attention paid by trials to pre-screening counselling should be 
translated to a screening service.  Information and communication strategies will need to be 
developed that prepare individuals psychologically for abnormal screening results so that they are 
fully informed. 
The UKLS study is therefore a hugely important and timely contribution, which has greatly advanced 
our understanding of the psychosocial impact of lung cancer screening and those sub-groups who 
may be more vulnerable to experiencing distress.  It provides the foundations for future research to 
investigate risk factors for increased distress, to examine the full spectrum of psychological 
responses to lung cancer screening in the health service context, and to develop supportive 
communication strategies and interventions that further increase the benefits of screening.   
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